Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 38: 628-635, 1992;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Klee, G. G.
Right arrow Articles by Kao, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klee, G. G.
Right arrow Articles by Kao, P. C.

Clinical Chemistry, Vol 38, 628-635, Copyright © 1992 by American Association for Clinical Chemistry

Multisite immunochemiluminometric assay for simultaneously measuring whole-molecule and amino-terminal fragments of human parathyrin

GG Klee, CM Preissner, PG Schryver, RL Taylor and PC Kao
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905.

The immunochemiluminometric assay described uses immobilized anti-human parathyrin (parathyroid hormone, hPTH)(1-44) and anti-hPTH(44-68) antisera and acridinium ester-labeled anti-hPTH(1-34) to simultaneously measure both intact hPTH and its amino-terminal fragments. Results by the assay correlate well with those by a cAMP-based bioassay and the Nichols Allegro immunoradiometric assay. The minimal detection limit is 0.08 pmol/L. The normal range is 1.0-5.0 pmol/L, and values are higher in older women. About 90% of study patients with surgically proven parathyroid adenomas had above-normal preoperative PTH concentrations, whereas patients with hypercalcemia of malignancy had normal or suppressed values. This assay was designed to detect both intact PTH and amino-terminal PTH fragments; however, chromatographic fractionation of pools of primary and secondary hyperparathyroid plasma showed virtually no amino-terminal fragment activity. Nonetheless, the design is important because the absence of carboxyl-terminal binding sites prevents interference by carboxyl-terminal fragments and because bioactive amino-terminal fragments will react in the assay if they are present in the patients' sera or if they are produced by in vitro proteolysis of intact PTH.


The following articles in journals at HighWire Press have cited this article:


Home page
 Mayo Clin Proc.Home page
P. J. Tebben, R. J. Singh, B. L. Clarke, and R. Kumar
Fibroblast Growth Factor 23, Parathyroid Hormone, and 1{alpha},25-Dihydroxyvitamin D in Surgically Treated Primary Hyperparathyroidism
Mayo Clin. Proc., December 1, 2004; 79(12): 1508 - 1513.
[Abstract] [PDF]

Home page
 Mayo Clin Proc.Home page
R. J. Singh and R. Kumar
Fibroblast Growth Factor 23 Concentrations in Humoral Hypercalcemia of Malignancy and Hyperparathyroidism
Mayo Clin. Proc., July 1, 2003; 78(7): 826 - 829.
[Abstract] [PDF]

Home page
 NEJMHome page
Q. Cai, S. F. Hodgson, P. C. Kao, V. A. Lennon, G. G. Klee, A. R. Zinsmiester, and R. Kumar
Inhibition of Renal Phosphate Transport by a Tumor Product in a Patient with Oncogenic Osteomalacia
N. Engl. J. Med., June 9, 1994; 330(23): 1645 - 1649.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American Association for Clinical Chemistry.